ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
40
HLB completes Pre-NDA meeting with FDA
admin
2019.10.25
39
HLB, Elevar agree to triangular merger deal to speed up Rivoceranib development
admin
2019.10.16
38
Rivoceranib named Best of ESMO 2019
admin
2019.10.02
37
Elevar announces results from the ANGEL trial
admin
2019.09.29
36
Elevar therapeutics and Neopharma establish a JV for the commercialization of Rivoceranib
admin
2019.09.26
35
Elevar Therapeutics announces ANGEL Trial Podium Presentation at ESMO
admin
2019.09.20
34
FDA approves HLB's phase 1b/2 clinical trial for Colorectal Cancer
admin
2019.08.26
33
FDA approves HLB's phase 2 clinical trial for Adenoid Cystic Carcinoma
admin
2019.08.22
32
HLB Completes application for Pre-NDA Meeting with FDA
admin
2019.08.19
31
LSK BioPharma and Jiangsu Hengrui Medicine announce enrollment of the first patient in a phase 3 clinical study
admin
2019.06.30
<<
<
11
12
13
14
15